The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
NCT ID: NCT00321321
Last Updated: 2015-07-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
12 participants
INTERVENTIONAL
2006-05-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Beta-Cell Function After Near-Normalisation of Blood Glucose
NCT00612950
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes
NCT04228484
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sulfonylurea
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diet and/or metformin treatment
* HbA1c \> 7,0% for metformin treated patients
* HbA1c \> 7,5% for diet treated patients
* Age: 18 years or older
* 25 \> BMI \> 40 kg/m2
* Signed informed consent
* Sufficient birth control in case of child bearing capacity
Exclusion Criteria
* Diabetic nephropathy with s-creatinine \> 130 microM and/or macroalbuminuria
* Liver disease (ALAT \> 2 x normal value)
* CAD (NYHA group III or IV)
* Positive screening for islet-cell and/or GAD-65 autoantibodies
* Type 1 diabetes i first degree relatives
* Gastrointestinal surgery with intestinal resection
* Anemia
* Pregnancy and/or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gentofte University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kasper Aaboe, M.D.
Role: PRINCIPAL_INVESTIGATOR
Gentofte University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine, Gentofte University Hospital
Hellerup, Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KA-05011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.